Literature DB >> 28822642

A suicidal strain of Listeria monocytogenes is effective as a DNA vaccine delivery system for oral administration.

Shubhra Sinha1, Cheng-Yi Kuo1, Joan K Ho1, Paul J White1, Jalal A Jazayeri1, Colin W Pouton2.   

Abstract

In this study we determined the in vivo activity of model ovalbumin vaccines delivered by direct intramuscular delivery of plasmid DNA or oral delivery using a recombinant suicidal Listeria monocytogenes strain (rsΔ2). In a previous report we described how rsΔ2 is capable of delivering luciferase, as protein or DNA, in vitro, into non-dividing intestinal epithelial cells (Kuo et al., 2009). This is achieved by engineering a dual expression shuttle vector, pDuLX-Luc, that replicates in E. coli and rsΔ2 and drives gene expression from the Listeria promoter (Phly) as well as the eukaryotic cytomegalovirus promoter (CMV), thereby delivering both protein and plasmid DNA to the cell cytoplasm. For the current in vivo study rsΔ2 containing pDuLX-OVA was used to deliver both ovalbumin protein and the mammalian expression plasmid by the oral route. Controls were used to investigate the activity of this system versus positive and negative controls, as well as quantifying activity against direct intramuscular injection of expression plasmids. Oral administration of rsΔ2(pDuLX-OVA) produced significant titres of antibody and was effective at inducing targeted T-cell lysis (approximately 30% lysis relative to an experimental positive control, intravenous OVA-coated splenocytes+lipopolysaccharide). Intramuscular injection of plasmids pDuLX-OVA or p3L-OVA (which lacks the prokaryotic promoter) also produced significant CTL-mediated cell lysis. The delivery of the negative control rsΔ2 (pDuLX-Luc) confirmed that the observed activity was induced specifically by the ovalbumin vaccination. The data suggest that the oral activity of rsΔ2(pDuLX-OVA) is explained by delivery of OVA protein, expressed in rsΔ2 from the prokaryotic promoter present in pDuLX-OVA, but transfection of mammalian cells in vivo may also play a role. Antibody titres were also produced by oral delivery (in rsΔ2) of the p3L-OVA plasmid in which does not include a prokaryotic promoter. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell-mediated immunity; Humoral immunity; Intramuscular vaccine delivery; Listeria monocytogenes; Oral vaccine delivery; Vaccines

Mesh:

Substances:

Year:  2017        PMID: 28822642     DOI: 10.1016/j.vaccine.2017.08.014

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Computational tools for modern vaccine development.

Authors:  Andaleeb Sajid; Yogendra Singh; Pratyoosh Shukla
Journal:  Hum Vaccin Immunother       Date:  2019-12-18       Impact factor: 3.452

Review 2.  Vaccination against Bacterial Infections: Challenges, Progress, and New Approaches with a Focus on Intracellular Bacteria.

Authors:  Anke Osterloh
Journal:  Vaccines (Basel)       Date:  2022-05-10

Review 3.  Live Bacterial Vectors-A Promising DNA Vaccine Delivery System.

Authors:  Valentina Yurina
Journal:  Med Sci (Basel)       Date:  2018-03-23

4.  A Potent and Effective Suicidal Listeria Vaccine Platform.

Authors:  William G Hanson; Erin L Benanti; Edward E Lemmens; Weiqun Liu; Justin Skoble; Meredith L Leong; Chris S Rae; Marcella Fassò; Dirk G Brockstedt; Chen Chen; Daniel A Portnoy; Thomas W Dubensky; Peter Lauer
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

Review 5.  Nucleic acid strategies for infectious disease treatments: The nanoparticle-based oral delivery route.

Authors:  Fengqian Chen; Qi Liu; Yang Xiong; Li Xu
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

Review 6.  Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies.

Authors:  Mariam Oladejo; Yvonne Paterson; Laurence M Wood
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.